树突状细胞在多发性硬化免疫治疗中的应用  

Immunotherapeutic potential of dendritic cells in multiple sclerosis

作　　者：刘彩云[1] 金涛[1] Cai-yun LIU;Tao JIN(Department of Neurology and Neuroscience Center,The First Hospital of Jilin University,Changchun 130021,Jilin,China)

机构地区：[1]吉林大学第一医院神经内科与神经科学中心,长春130021

出　　处：《中国现代神经疾病杂志》2024年第5期320-330,共11页Chinese Journal of Contemporary Neurology and Neurosurgery

基　　金：国家自然科学基金资助项目(项目编号:82171337)。

摘　　要：树突状细胞是机体功能最强的专职抗原呈递细胞,基于其亚型和环境信号在诱导炎症或耐受性免疫反应中起关键作用。树突状细胞对于多发性硬化的发生和疾病进展至关重要。在多发性硬化动物模型和早期临床试验中,诱导耐受性树突状细胞具有强大的治疗潜力。与体外诱导耐受性树突状细胞相比,特异性靶向其表面受体的体内诱导策略表现出更大的前景和优势。本文总结树突状细胞在调节免疫耐受和多发性硬化发生和进展中的作用,并对有潜力作为靶点的树突状细胞表面特异性受体进行梳理,以为耐受性免疫治疗多发性硬化提供新的靶点和策略。Dendritic cells(DCs)are the most potent professional antigen-presenting cells(APCs),which play a pivotal role in inducing either inflammatory or tolerogenic response based on their subtypes and environmental signals.DCs are critical for initiation and progression of multiple sclerosis(MS).Induction of tolerogenic DCs(tolDCs)with powerful therapeutic potential has been well-established to combat autoimmune responses in laboratory models and early clinical trials.In contrast to in vitro tolDCs induction,in vivo elicitation by specifically targeting multiple cell-surface receptors has shown greater promise with more advantages.Here,we summarize the role of DCs in governing immune tolerance and in the process of initiating and perpetuating MS.We then highlight the most promising cell-surface receptors expressed on DCs currently being explored as the viable pharmacological targets through antigen delivery to generate tolDCs in vivo,to guide feasible immunotherapeutic strategies.

关 键 词：树突状细胞(非MeSH词) 多发性硬化 免疫疗法 综述 

分 类 号：R744.51[医药卫生—神经病学与精神病学]